Sorry, you need to enable JavaScript to visit this website.

XALKORI® (crizotinib) Indications and Usage

1 INDICATIONS AND USAGE

XALKORI is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test [see Dosage and Administration (2.1)].

What's New

No Current Announcements.

Search

Please enter your search term(s) for XALKORI®